Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The standard therapy for preventing copper accumulation in Wilson's disease, D-penicillamine, has been a life-saving drug, but it has many side effects and some patients are completely intolerant. We have been using oral zinc as another approach to the therapy for Wilson's disease, with copper balance studies as the key initial assessment of the adequacy of a given dose or regimen of zinc therapy. We earlier reported that an intensive regimen of zinc (zinc taken every 4 hr) was effective in controlling copper balance. We have now shown with balance studies that a simplified zinc therapy regimen of 50 mg zinc taken 3 times per day is effective in controlling copper balance. Preliminary work presented here with other simplified regimens also indicate their effectiveness. These studies increase the data base, in terms of copper balance, for zinc therapy of Wilson's disease, and expand the dose range and regimens of zinc which have been shown to control copper balance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral zinc therapy for Wilson's disease
BREWER, G. J., HILL, G. M., PRASAD, A. S., COSSACK, Z. T., & RABBANI, P. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-3-314 · Cited by 244
Self-citation
Cited by
Ala, A., Walker, A. P., Ashkan, K., Dooley, J. S., & Schilsky, M. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60196-2 · Cited by 1,446
Diagnosis and treatment of Wilson disease: An update
Roberts, E. A., & Schilsky, M. L. (2008) · Hepatology · doi:10.1002/hep.22261 · Cited by 1,299
The molecular mechanisms of copper metabolism and its roles in human diseases
Chen, J., Jiang, Y., Shi, H., Peng, Y., Fan, X., & Li, C. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02412-2 · Cited by 475
A Practice Guideline on Wilson Disease
Roberts, E. A., & Schilsky, M. L. (2003) · Hepatology · doi:10.1053/jhep.2003.50252 · Cited by 452
Zinc: health effects and research priorities for the 1990s.
Walsh, C. T., Sandstead, H. H., Prasad, A. S., Newberne, P. M., & Fraker, P. J. (1994) · Environmental Health Perspectives · doi:10.1289/ehp.941025 · Cited by 434
Self-citationDanks, D. M. (1988) · Annual Review of Nutrition · doi:10.1146/annurev.nu.08.070188.001315 · Cited by 341
Brewer, G. J., Hedera, P., Kluin, K. J., Carlson, M., Askari, F., Dick, R. B., Sitterly, J., & Fink, J. K. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.379 · Cited by 308
Self-citationTreatment of Wilson's disease with zinc: XV long-term follow-up studies
Brewer, G. J., Dick, R. D., Johnson, V. D., Brunberg, J. A., Kluin, K. J., & Fink, J. K. (1998) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(98)90039-7 · Cited by 268
Self-citationEfficacy and Safety of Oral Chelators in Treatment of Patients With Wilson Disease
Weiss, K. H., Thurik, F., Gotthardt, D. N., Schäfer, M., Teufel, U., Wiegand, F., Merle, U., Ferenci–Foerster, D., Maieron, A., Stauber, R., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.03.012 · Cited by 254
Practical recommendations and new therapies for Wilson's disease
Brewer, G. J. (1995) · Drugs · doi:10.2165/00003495-199550020-00004 · Cited by 92
Self-citationModulation of tau phosphorylation by environmental copper
Voss, K., Harris, C., Ralle, M., Duffy, M., Murchison, C., & Quinn, J. F. (2014) · Translational Neurodegeneration · doi:10.1186/2047-9158-3-24 · Cited by 83
“Similarly, human subjects with Wilson’s disease tolerate oral zinc therapy and achieve a negative copper balance [35], so clinical application (with appropriate monitoring) of zinc therapy for AD is at least plausible.”
Background
Metadata
- Authors
- Hill, G. M., Brewer, G. J., Prasad, A. S., Hydrick, C. R., & Hartmann, D. E.
- Venue
- Hepatology
- Published
- 1987-05
- Volume
- 7
- Issue
- 3
- Pages
- 522-528
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2125848406
- Cited by
- 112
- References
- 1
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.